Clinical Trials Browser

Pituitary Neoplasms × Ipilimumab × 90 days × Clear all

NCT04042753 2026-06-02

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Phase 2 Completed

Pituitary Diseases, Pituitary Neoplasms